A unified nomenclature and amino acid numbering for human PTEN

Rafael Pulido; Suzanne J. Baker; Joao T. Barata; Arkaitz Carracedo; Victor J. Cid; Ian D. Chin-Sang; Vrushank Davé; Jeroen Den Hertog; Peter Devreotes; Britta J. Eickholt; Charis Eng; Frank B. Furnari; Maria Magdalena Georgescu; Arne Gericke; Benjamin Hopkins; Xeujun Jiang; Seung Rock Lee; Mathias Lösche; Prerna Malaney; Xavier Matias-Guiu; María Molina; Pier Paolo Pandolfi; Ramon Parsons; Paolo Pinton; Carmen Rivas; Rafael M. Rocha; Manuel S. Rodríguez; Alonzo H. Ross; Manuel Serrano; Vuk Stambolic; Bangyan Stiles; Akira Suzuki; Seong Seng Tan; Nicholas K. Tonks; Lloyd C. Trotman; Nicolas Wolff; Rudiger Woscholski; Hong Wu; Nicholas R. Leslie

doi:10.1126/scisignal.2005560

A unified nomenclature and amino acid numbering for human PTEN

Rafael Pulido^*, Suzanne J. Baker, Joao T. Barata, Arkaitz Carracedo, Victor J. Cid, Ian D. Chin-Sang, Vrushank Davé, Jeroen Den Hertog, Peter Devreotes, Britta J. Eickholt, Charis Eng, Frank B. Furnari, Maria Magdalena Georgescu, Arne Gericke, Benjamin Hopkins, Xeujun Jiang, Seung Rock Lee, Mathias Lösche, Prerna Malaney, Xavier Matias-GuiuMaría Molina, Pier Paolo Pandolfi, Ramon Parsons, Paolo Pinton, Carmen Rivas, Rafael M. Rocha, Manuel S. Rodríguez, Alonzo H. Ross, Manuel Serrano, Vuk Stambolic, Bangyan Stiles, Akira Suzuki, Seong Seng Tan, Nicholas K. Tonks, Lloyd C. Trotman, Nicolas Wolff, Rudiger Woscholski, Hong Wu, Nicholas R. Leslie

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

51 Citations (Scopus)

35 Downloads (Pure)

Abstract

The tumor suppressor PTEN is a major brake for cell transformation, mainly due to its phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P₃] phosphatase activity that directly counteracts the oncogenicity of phosphoinositide 3-kinase (PI3K). PTEN mutations are frequent in tumors and in the germ line of patients with tumor predisposition or with neurological or cognitive disorders, which makes the PTEN gene and protein a major focus of interest in current biomedical research. After almost two decades of intense investigation on the 403-residue-long PTEN protein, a previously uncharacterized form of PTEN has been discovered that contains 173 amino-terminal extra amino acids, as a result of an alternate translation initiation site. To facilitate research in the field and to avoid ambiguities in the naming and identification of PTEN amino acids from publications and databases, we propose here a unifying nomenclature and amino acid numbering for this longer form of PTEN.

Original language	English
Article number	pe15
Journal	Science Signaling
Volume	7
Issue number	332
DOIs	https://doi.org/10.1126/scisignal.2005560
Publication status	Published - 1 Jul 2014

ASJC Scopus subject areas

Biochemistry
Cell Biology
Molecular Biology

Access to Document

10.1126/scisignal.2005560

Download pdf
This is the author’s version of the work. It is posted here by permission of the AAAS for personal use, not for redistribution. The definitive version was published in Science Signaling on 01/07/2014, vol. 7, DOI: 10.1126/scisignal.2005560
Accepted author manuscript, 323 KBLicence: All Rights Reserved

Cite this

Pulido, R., Baker, S. J., Barata, J. T., Carracedo, A., Cid, V. J., Chin-Sang, I. D., Davé, V., Den Hertog, J., Devreotes, P., Eickholt, B. J., Eng, C., Furnari, F. B., Georgescu, M. M., Gericke, A., Hopkins, B., Jiang, X., Lee, S. R., Lösche, M., Malaney, P., ... Leslie, N. R. (2014). A unified nomenclature and amino acid numbering for human PTEN. Science Signaling, 7(332), Article pe15. https://doi.org/10.1126/scisignal.2005560

@article{9535c68f3aa84b71a993d5a9ecbeec98,

title = "A unified nomenclature and amino acid numbering for human PTEN",

abstract = "The tumor suppressor PTEN is a major brake for cell transformation, mainly due to its phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3] phosphatase activity that directly counteracts the oncogenicity of phosphoinositide 3-kinase (PI3K). PTEN mutations are frequent in tumors and in the germ line of patients with tumor predisposition or with neurological or cognitive disorders, which makes the PTEN gene and protein a major focus of interest in current biomedical research. After almost two decades of intense investigation on the 403-residue-long PTEN protein, a previously uncharacterized form of PTEN has been discovered that contains 173 amino-terminal extra amino acids, as a result of an alternate translation initiation site. To facilitate research in the field and to avoid ambiguities in the naming and identification of PTEN amino acids from publications and databases, we propose here a unifying nomenclature and amino acid numbering for this longer form of PTEN.",

author = "Rafael Pulido and Baker, {Suzanne J.} and Barata, {Joao T.} and Arkaitz Carracedo and Cid, {Victor J.} and Chin-Sang, {Ian D.} and Vrushank Dav{\'e} and {Den Hertog}, Jeroen and Peter Devreotes and Eickholt, {Britta J.} and Charis Eng and Furnari, {Frank B.} and Georgescu, {Maria Magdalena} and Arne Gericke and Benjamin Hopkins and Xeujun Jiang and Lee, {Seung Rock} and Mathias L{\"o}sche and Prerna Malaney and Xavier Matias-Guiu and Mar{\'i}a Molina and Pandolfi, {Pier Paolo} and Ramon Parsons and Paolo Pinton and Carmen Rivas and Rocha, {Rafael M.} and Rodr{\'i}guez, {Manuel S.} and Ross, {Alonzo H.} and Manuel Serrano and Vuk Stambolic and Bangyan Stiles and Akira Suzuki and Tan, {Seong Seng} and Tonks, {Nicholas K.} and Trotman, {Lloyd C.} and Nicolas Wolff and Rudiger Woscholski and Hong Wu and Leslie, {Nicholas R.}",

year = "2014",

month = jul,

day = "1",

doi = "10.1126/scisignal.2005560",

language = "English",

volume = "7",

journal = "Science Signaling",

issn = "1945-0877",

publisher = "American Association for the Advancement of Science",

number = "332",

}

Pulido, R, Baker, SJ, Barata, JT, Carracedo, A, Cid, VJ, Chin-Sang, ID, Davé, V, Den Hertog, J, Devreotes, P, Eickholt, BJ, Eng, C, Furnari, FB, Georgescu, MM, Gericke, A, Hopkins, B, Jiang, X, Lee, SR, Lösche, M, Malaney, P, Matias-Guiu, X, Molina, M, Pandolfi, PP, Parsons, R, Pinton, P, Rivas, C, Rocha, RM, Rodríguez, MS, Ross, AH, Serrano, M, Stambolic, V, Stiles, B, Suzuki, A, Tan, SS, Tonks, NK, Trotman, LC, Wolff, N, Woscholski, R, Wu, H & Leslie, NR 2014, 'A unified nomenclature and amino acid numbering for human PTEN', Science Signaling, vol. 7, no. 332, pe15. https://doi.org/10.1126/scisignal.2005560

TY - JOUR

T1 - A unified nomenclature and amino acid numbering for human PTEN

AU - Pulido, Rafael

AU - Baker, Suzanne J.

AU - Barata, Joao T.

AU - Carracedo, Arkaitz

AU - Cid, Victor J.

AU - Chin-Sang, Ian D.

AU - Davé, Vrushank

AU - Den Hertog, Jeroen

AU - Devreotes, Peter

AU - Eickholt, Britta J.

AU - Eng, Charis

AU - Furnari, Frank B.

AU - Georgescu, Maria Magdalena

AU - Gericke, Arne

AU - Hopkins, Benjamin

AU - Jiang, Xeujun

AU - Lee, Seung Rock

AU - Lösche, Mathias

AU - Malaney, Prerna

AU - Matias-Guiu, Xavier

AU - Molina, María

AU - Pandolfi, Pier Paolo

AU - Parsons, Ramon

AU - Pinton, Paolo

AU - Rivas, Carmen

AU - Rocha, Rafael M.

AU - Rodríguez, Manuel S.

AU - Ross, Alonzo H.

AU - Serrano, Manuel

AU - Stambolic, Vuk

AU - Stiles, Bangyan

AU - Suzuki, Akira

AU - Tan, Seong Seng

AU - Tonks, Nicholas K.

AU - Trotman, Lloyd C.

AU - Wolff, Nicolas

AU - Woscholski, Rudiger

AU - Wu, Hong

AU - Leslie, Nicholas R.

PY - 2014/7/1

Y1 - 2014/7/1

N2 - The tumor suppressor PTEN is a major brake for cell transformation, mainly due to its phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3] phosphatase activity that directly counteracts the oncogenicity of phosphoinositide 3-kinase (PI3K). PTEN mutations are frequent in tumors and in the germ line of patients with tumor predisposition or with neurological or cognitive disorders, which makes the PTEN gene and protein a major focus of interest in current biomedical research. After almost two decades of intense investigation on the 403-residue-long PTEN protein, a previously uncharacterized form of PTEN has been discovered that contains 173 amino-terminal extra amino acids, as a result of an alternate translation initiation site. To facilitate research in the field and to avoid ambiguities in the naming and identification of PTEN amino acids from publications and databases, we propose here a unifying nomenclature and amino acid numbering for this longer form of PTEN.

AB - The tumor suppressor PTEN is a major brake for cell transformation, mainly due to its phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3] phosphatase activity that directly counteracts the oncogenicity of phosphoinositide 3-kinase (PI3K). PTEN mutations are frequent in tumors and in the germ line of patients with tumor predisposition or with neurological or cognitive disorders, which makes the PTEN gene and protein a major focus of interest in current biomedical research. After almost two decades of intense investigation on the 403-residue-long PTEN protein, a previously uncharacterized form of PTEN has been discovered that contains 173 amino-terminal extra amino acids, as a result of an alternate translation initiation site. To facilitate research in the field and to avoid ambiguities in the naming and identification of PTEN amino acids from publications and databases, we propose here a unifying nomenclature and amino acid numbering for this longer form of PTEN.

U2 - 10.1126/scisignal.2005560

DO - 10.1126/scisignal.2005560

M3 - Article

C2 - 24985344

AN - SCOPUS:84903768994

SN - 1945-0877

VL - 7

JO - Science Signaling

JF - Science Signaling

IS - 332

M1 - pe15

ER -

A unified nomenclature and amino acid numbering for human PTEN

Abstract

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this